From: Therapeutic angiogenesis and tissue revascularization in ischemic vascular disease
First author | Phase year | Disease | Treatment | Subject(n) treatment/control | Findings | Ref |
---|---|---|---|---|---|---|
Gao, L.R | Phase I/II 2015 | CHD | Intracoronary infusion of HUCMSCs | 58/58 | Myocardial viability/perfusion increase LVEF increase Proven safety | [113] |
Qayyum, A.A | Phase II 2019 | CHD | Intramyocardial injections of ADSCs | 40/20 | Low incidence of angina Chest discomfort reduced NYHA classification reduced | [114] |
Mathiasen, A.B | Phase II 2019 | CHD | Intramyocardial injections of BMSCs | 40/20 | LVESV reduced Cardiac pump function and myocardial mass improved Myocardial scar tissue reduced Fewer admissions for angina symptoms | [115] |
Jaillard, A | Phase I 2020 | CAD | Intravenous autologous MSC treatment | 20/11 | Proven safety and feasibility | [94] |